Smartlab Europe

Drug Research

Making Immunotherapy Work In The Tumour Microenvironment

One of the latest studies that takes into account the tumour microenvironment of pancreatic cancer puts forth the cause that tumour cells are resistant to immunotherapy, resulting in new strategies for treatment. The study, which is led by Johns Hopkins...

UK All Set For New Drug Manufacturing Regulatory Framework

As UK will introduce a customised framework for the innovative medicines’ regulation manufactured at the point where the care is received by the patient, it will be the first country to do so, as per the Medicine and Healthcare...

There Is More To VEXAS Syndrome Than Previously Perceived

As per a recent study that was published in JAMA, a not so well-known syndrome with high mortality has a much higher prevalence than it was thought. The syndrome called VEXAS was first identified in 2020 in patients who...

Anti-Cancer Chemistry For Skullcap Fit For Modern Drugs

A collaboration between Chinese researchers and UK researchers has led to the unlocking of facilities related to evolutionary secrets that help the medicinal herb called barbed skullcap develop cancer-fighting compounds. The CEPAMS partnership made use of DNA sequencing tech to...

Strict Steps In Supply Chain Against Contamination By WHO

The World Health Organization has urged regulators, suppliers, as well as medicine manufacturers to take strict steps against medicines in the supply chain that are contaminated. This is due to the recent instances of over-the-counter cough syrups which had...

Novel Method On Large DNA Sequences Insertion Successful

Recent work by researchers at Massachusetts General Hospital (MGH) in the US has improved the accuracy of inserting long DNA fragments into genomes. This method might be used to introduce an entire wild-type or normal substitute gene, acting as a...

EyePoint Pharmaceuticals to Build GMP Mfg. Facility in Northbridge, MA

EyePoint Pharmaceuticals, Inc., a company developing and commercializing therapeutics for serious eye disorders, has entered into a lease agreement to design and construct a 40,000-sq.-ft. manufacturing facility in Northbridge, MA to support the global manufacturing of programs, including EYP-1901...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »